A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
about
The TXP motif in the second transmembrane helix of CCR5. A structural determinant of chemokine-induced activationTAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humansSpirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitroA microdomain formed by the extracellular ends of the transmembrane domains promotes activation of the G protein-coupled alpha-factor receptorNeutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitorsBinding modes of CCR5-targetting HIV entry inhibitors: partial and full antagonistsPotent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1Chemokine blockade: a new era in the treatment of rheumatoid arthritis?Structure modeling of all identified G protein-coupled receptors in the human genomeCurrent perspectives on HIV-1 antiretroviral drug resistanceP2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor InteractionsHIV entry inhibitors: mechanisms of action and resistance pathwaysThe neuropathogenesis of AIDSSpecific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivoInhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replicationV3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodiesToward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptorsTwo HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entryAn inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitorsStructural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico studyMolecular dynamics simulations on SDF-1alpha: binding with CXCR4 receptorCombinatorial approaches to the prevention and treatment of HIV-1 infectionC-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic.Closing the door to human immunodeficiency virus.Vaccinia virus activation of CCR5 invokes tyrosine phosphorylation signaling events that support virus replicationConstitutive activation of CCR5 and CCR2 induced by conformational changes in the conserved TXP motif in transmembrane helix 2.Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library.Phosphatidylcholine-specific phospholipase C activation is required for CCR5-dependent, NF-kB-driven CCL2 secretion elicited in response to HIV-1 gp120 in human primary macrophages.Association of progressive CD4(+) T cell decline in SIV infection with the induction of autoreactive antibodiesAnalysis of primary resistance mutations to HIV-1 entry inhibitors in therapy naive subtype C HIV-1 infected mother-infant pairs from Zambia.Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cellsMode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virusVariants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycanAnti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1.A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer.Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.Interaction with CD4 and antibodies to CD4-induced epitopes of the envelope gp120 from a microglial cell-adapted human immunodeficiency virus type 1 isolate
P2860
Q24291042-0DF0EC40-DB30-47B4-AC19-FFD96DA8D790Q24537285-3BE53681-A5C3-430E-846F-58BFDAC9F6D6Q24563937-64F8147D-E230-4881-8348-A27328D60B12Q24607973-BBAE4D18-3894-462B-83AE-5BCE44B3937CQ24655129-95CB186B-D1C0-4152-A78E-84F98443858FQ24658283-61F5DCDD-03F4-4B9A-92CE-BFAD900CA957Q24673555-D360AF77-40B6-4AA9-A3BD-FBC43C0FE838Q24800857-7163500D-B949-45CE-9309-1218E17AA75BQ25256886-47D4ED11-2DC3-432F-8302-54911A2EC2EFQ26852626-E615F057-DD8D-485C-AB61-CF6D8C0B5EDEQ27321418-618350CA-AF90-4A7B-BB2C-13CB9F6A5AF7Q28296162-F564C0AD-B71A-4B8E-AD4E-7B93314FD2B5Q28300983-7EADA761-2EDA-4395-9EF1-9B6F8B6ADE39Q28344310-FE13E08F-6D6D-477D-8DC1-EBE9AA3F17FEQ28345395-D1297448-4217-4A77-B195-FAD2A33A5CCCQ28362194-7E99B5FF-004B-47FB-8B67-F1B69BB152EEQ28364133-3D1C5783-A2C6-4E73-B36C-BB65577BD31BQ28469283-095CDB41-B416-49F7-BA06-262263B168ACQ28472202-71A2FC18-1A7A-4060-B0A2-11BEC5F04717Q28475912-BBB63899-D46E-49F5-B0EB-474F32945EACQ28477736-342DE116-46AF-4815-90C7-C4B3EB9B07B2Q28481687-93A95E8E-62CD-4EAA-961D-96AE6EE3B947Q30332403-C56E2F03-E0D6-4DBC-A0E9-8F0B1529D850Q30400060-523D54FE-457B-47AB-BF4B-9C8AF7DE88BDQ30422545-6BCB3756-ADFA-4C0C-8DFF-865D6EB65C1FQ30428089-AF501E6D-2498-400C-80F1-69836F9216FAQ30540518-D7305B09-1733-4BFD-94DE-FC0361AE8295Q30956674-3DCC2FC7-5B5F-40C7-9DF5-FD3087E70D53Q33218075-72119425-348B-4171-B0F1-775C291126CFQ33315307-CE9C6100-20BE-4416-BE40-928DE443080FQ33384065-9DECA8B6-302D-4A69-A1EA-5904FDDC56B7Q33597247-35BCD4EE-552E-4E8A-930A-D51EAF3E5F30Q33613769-807928D2-9FBB-4D06-9E91-F53577497955Q33686847-B3EDF2DF-454F-428E-9B65-696F23B9580DQ33707328-F837A4BF-9C1A-49E3-850A-75D7165C6633Q33707333-FE0A8C9B-2D73-47D5-BE5B-F24D8484E0CBQ33718391-09FA281D-5D79-48E1-A2CF-1EFC2E7663E8Q33725702-AA75817D-C93C-41DE-8199-84EFAB73C77EQ33780620-CD93DF05-BABE-4E1C-8986-D64A6B31BAACQ33788874-4E331608-9A2C-42BE-B72A-120C6AA919B1
P2860
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
A binding pocket for a small m ...... transmembrane helices of CCR5
@ast
A binding pocket for a small m ...... transmembrane helices of CCR5
@en
A binding pocket for a small m ...... transmembrane helices of CCR5
@nl
type
label
A binding pocket for a small m ...... transmembrane helices of CCR5
@ast
A binding pocket for a small m ...... transmembrane helices of CCR5
@en
A binding pocket for a small m ...... transmembrane helices of CCR5
@nl
prefLabel
A binding pocket for a small m ...... transmembrane helices of CCR5
@ast
A binding pocket for a small m ...... transmembrane helices of CCR5
@en
A binding pocket for a small m ...... transmembrane helices of CCR5
@nl
P2093
P2860
P3181
P356
P1476
A binding pocket for a small m ...... transmembrane helices of CCR5
@en
P2093
D A Thompson
E G Cormier
F A Kajumo
P2860
P304
P3181
P356
10.1073/PNAS.090576697
P407
P577
2000-05-01T00:00:00Z